We report the safety and immunogenicity of a fourth booster dose of PHH-1V against the most prevalent Omicron SARS-CoV-2 variants in Spain.
Safety and Immunogenicity of PHH-1V Booster Against SARS-CoV-2 Variants, Including Omicron Subvariants: Results from a Phase IIb Open-Label Extension Study
COVID-19
Appeared in
Human Vaccines & Immunotherapeutics
Phase IIb HIPRA-HH-2 study results showed that PHH-1V as first booster dose elicited a strong and sustained neutralising antibody response against various SARS-CoV-2 variants.